Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care

BACKGROUND: Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. STUDY QUESTION: What is the effectiveness of rivaroxaban versus the standard of care (S...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Health Econ Outcomes Res
Autori principali: Peacock, W. Frank, Coleman, Craig I., Wells, Phil, Fermann, Gregory J., Wang, Li, Baser, Onur, Schein, Jeff, Crivera, Concetta
Natura: Artigo
Lingua:Inglês
Pubblicazione: Columbia Data Analytics, LLC 2019
Soggetti:
Cardiovascular Conditions
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7299482/
https://ncbi.nlm.nih.gov/pubmed/32685588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36469/9936
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi